About Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
The Sant’Orsola-Malpighi Polyclinic is a university and public hospital. The Polyclinc is the largest hospital in Italy, and the first of the four public hospitals of the city of Bologna. The Polyclinic has approximately 1,535 beds and 5,153 employees.
There are 1,535 beds in Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica.
Clinical Trials at Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
During the past decade, Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 10 clinical trials were completed, i.e. on
average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 3 clinical trials were completed. i.e. 50%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica"
#1 collaborator was "Breast International Group" with 2 trials as a collaborator, "Exelixis" with 2 trials as a collaborator, "Istituto Toscano Tumori" with 2 trials as a collaborator, "AOU S. Orsola Malpighi - Clinical Trial Office" with 1 trials as a collaborator and "AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were
collaborators in the rest 17 trials.
Clinical Trials Conditions at Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica" are
"Breast Cancer" (6 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Gastric Cancer" (2 trials), "Carcinoma, Renal Cell" (1 trials) and "Carcinoma, Transitional Cell" (1 trials). Many other conditions were trialed in "Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica" in a lesser frequency.
Clinical Trials Intervention Types at Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
Most popular intervention types in "Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica" are "Drug" (21 trials) and "Other" (4 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (10 trials), "Placebo" (6 trials), "Trastuzumab" (5 trials), "Docetaxel" (4 trials) and "Paclitaxel" (4 trials). Other intervention names were less common.
Clinical Trials Genders at Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
The vast majority of trials in "Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica" are
20 trials for "All" genders and 2 trials for "Female" genders.
Clinical Trials Status at Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
Currently, there are NaN active trials in "Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica".
undefined are not yet recruiting,
3 are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 13 completed trials in Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, 0 "Phase 1"
clinical trials were conducted, 6 "Phase 2" clinical
trials and 15 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 0 trials that are defined as “Not Applicable".